Aprea Therapeutics Announces Closing of Oversubscribed $30M Private Placement
“This transformational financing is a significant commitment by top-tier biotech investors who believe in the potential of APR1-1051 to impact the lives of cancer patients,” said Oren Gilad, Ph.D., President and CEO of Aprea. “We believe the proceeds will accelerate the advancement of the ongoing ACESOT-1051 study. Our immediate goal is to expand evaluation of APR-1051 in biologically selected tumor populations where we believe WEE1 inhibition may have meaningful therapeutic relevance. We plan to enroll at least 50 patients with uterine serous carcinoma (USC) and cyclin E-overexpressing, platinum-resistant ovarian cancer (PROC). We believe this strategy will sharpen the clinical development path for APR-1051 and accelerate insight generation in biomarker-defined patient populations most likely to benefit from WEE1 inhibition.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.